Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stefania Giaquinta"'
Autor:
Roberto Sabbatini, Matteo Santoni, Cristina Masini, Stefania Di Girolamo, Francesco Carrozza, Sebastiano Buti, Stefania Giaquinta, Cinzia Baldessari, Alessio Cortellini, Marta Venturelli, Roberto D'Amico, Francesco Caputo, Giuseppe Fornarini, Roberto Iacovelli, Umberto Basso, Camillo Porta, Sabrina Rossetti, Federica Iannuzzi, Sergio Bracarda, Stefania Pipitone, Pasquale Mighali, Maria Giuseppa Vitale, Luca Galli, Claudia Caserta, Paolo Andrea Zucali, Giovanna Vitale, Sara Balduzzi, Sarah Scagliarini
Publikováno v:
Clinical Genitourinary Cancer. 18:477-488
Background Immunotherapy has brought clinical benefits to patients with metastatic renal cell cancer (mRCC). Most patients tolerate immunotherapy but serious immune-related adverse events (irAEs) have been reported. Some studies indicate a correlatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738b62c79124980075cd05e9b4fd2b64
https://doi.org/10.1016/j.clgc.2020.05.010
https://doi.org/10.1016/j.clgc.2020.05.010
Autor:
Daniela Bartoletti, Lucia Catani, Stefania Giaquinta, Francesca Palandri, Nicola Vianelli, Federica D'Ambrosio, Michele Cavo, Emanuele Sutto, Giuseppe Auteri
Publikováno v:
British Journal of Haematology
na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70afa79d0aed49cd07a1b225af73d6ab
http://europepmc.org/articles/PMC7753380
http://europepmc.org/articles/PMC7753380
Autor:
Andrea Angelo, Martoni, Francesca, Di Fabio, Barbara, Melotti, Stefania, Giaquinta, Monica, Guaraldi
Publikováno v:
Anticancer research. 26(2B)
The rationale for planned sequential chemotherapy is based on the principle that sequential administration of non-cross-resistant cytotoxic agents has the advantage of eliminating additive toxicity and permitting the delivery of full doses of each dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9ae5383783583713ee45fcbb14f7486d
https://pubmed.ncbi.nlm.nih.gov/16619564
https://pubmed.ncbi.nlm.nih.gov/16619564
Autor:
Carmine, Pinto, Antonella, Marino, Vincenzo, De Pangher Manzini, Giovanni, Benedetti, Domenico, Galetta, Paola, Mazzanti, Guido, Del Conte, Davide, dell'Amore, Edera, Piana, Stefania, Giaquinta, Massimo, Lopez, Andrea, Martoni
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 52(2)
We performed a multicenter phase II trial to evaluate the impact on the activity, efficacy, symptom control and safety of using two active regimens in a sequential schedule (cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin) as fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a31b97825af4c551e606054a41d2fd97
https://pubmed.ncbi.nlm.nih.gov/16542747
https://pubmed.ncbi.nlm.nih.gov/16542747